S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NYSE:BSXBoston Scientific Stock Price, Forecast & News

$39.96
+0.65 (+1.65 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$39.36
Now: $39.96▼
$40.23
50-Day Range
$33.28
MA: $36.75▼
$39.81
52-Week Range
$24.10
Now: $39.96▼
$46.62
Volume6.50 million shs
Average Volume10.87 million shs
Market Capitalization$57.17 billion
P/E Ratio14.17
Dividend YieldN/A
Beta0.95
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Read More
Boston Scientific logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.07 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:BSX
Previous Symbol
CUSIP10113710
CIK885725
Webwww.bostonscientific.com
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.59
Current Ratio1.87
Quick Ratio1.38

Price-To-Earnings

Trailing P/E Ratio14.17
Forward P/E Ratio39.56
P/E Growth3.87

Sales & Book Value

Annual Sales$10.74 billion
Price / Sales5.33
Cash Flow$2.46 per share
Price / Cash Flow16.22
Book Value$10.91 per share
Price / Book3.66

Profitability

EPS (Most Recent Fiscal Year)$1.58
Net Income$4.70 billion
Net Margins39.18%
Return on Equity12.86%
Return on Assets5.76%

Miscellaneous

Employees36,000
Outstanding Shares1,430,675,000
Market Cap$57.17 billion
Next Earnings Date10/28/2020 (Estimated)
OptionableOptionable
$39.96
+0.65 (+1.65 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Boston Scientific (NYSE:BSX) Frequently Asked Questions

How has Boston Scientific's stock been impacted by COVID-19 (Coronavirus)?

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BSX shares have increased by 18.0% and is now trading at $39.96.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Boston Scientific?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Boston Scientific.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Boston Scientific.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) issued its earnings results on Wednesday, July, 29th. The medical equipment provider reported $0.08 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.12. The medical equipment provider had revenue of $2 billion for the quarter, compared to analyst estimates of $1.68 billion. Boston Scientific had a net margin of 39.18% and a return on equity of 12.86%. The company's quarterly revenue was down 23.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.39 earnings per share.
View Boston Scientific's earnings history.

What price target have analysts set for BSX?

24 Wall Street analysts have issued twelve-month price objectives for Boston Scientific's stock. Their forecasts range from $25.00 to $58.00. On average, they expect Boston Scientific's share price to reach $45.00 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price.
View analysts' price targets for Boston Scientific.

Has Boston Scientific been receiving favorable news coverage?

News headlines about BSX stock have trended negative on Thursday, according to InfoTrie. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Boston Scientific earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Boston Scientific.

Are investors shorting Boston Scientific?

Boston Scientific saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 17,060,000 shares, an increase of 52.3% from the May 14th total of 11,200,000 shares. Based on an average daily trading volume, of 12,480,000 shares, the days-to-cover ratio is presently 1.4 days.
View Boston Scientific's Short Interest.

Who are some of Boston Scientific's key competitors?

Some companies that are related to Boston Scientific include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and ABIOMED (ABMD).
View all competitors.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Bank of America (BAC), Walt Disney (DIS), Cisco Systems (CSCO), Paypal (PYPL), AT&T (T), Intel (INTC) and Micron Technology (MU).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the following people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 55, Pay $3.57M)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 54, Pay $1.28M)
  • Mr. Edward F. Mackey, Exec. VP of Operations (Age 57, Pay $1.13M)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 56, Pay $1.24M)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 47, Pay $1.07M)

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by many different institutional and retail investors. Top institutional investors include Viking Global Investors LP (1.32%), Newport Trust Co (0.63%), Swiss National Bank (0.41%), Sumitomo Mitsui Trust Holdings Inc. (0.40%), Marshall Wace North America L.P. (0.37%) and Winslow Capital Management LLC (0.29%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori.
View institutional ownership trends for Boston Scientific.

Which institutional investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Senator Investment Group LP, Toronto Dominion Bank, Sumitomo Mitsui Trust Holdings Inc., Strs Ohio, Atalanta Sosnoff Capital LLC, Diamond Hill Capital Management Inc., and California Public Employees Retirement System. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, and Wendy Carruthers.
View insider buying and selling activity for Boston Scientific.

Which institutional investors are buying Boston Scientific stock?

BSX stock was purchased by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Locust Wood Capital Advisers LLC, SeaTown Holdings Pte. Ltd., FIL Ltd, State of Tennessee Treasury Department, Tocqueville Asset Management L.P., Fisher Asset Management LLC, and State of Wisconsin Investment Board. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu, and Williamson Scott.
View insider buying and selling activity for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $39.96.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $57.17 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe.

What is Boston Scientific's official website?

The official website for Boston Scientific is www.bostonscientific.com.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.